Latest News-CliniExpert

Vaxzevria is Highly Effective After One Dose Against Severe Disease or Hospitalisation Caused by Beta and Delta Variants of Concern

Real-world data from Canada showed 82% and 87% effectiveness after one dose against hospitalisation or death caused by Beta/Gamma and Delta variants respectively 23 July 2021 -- Results from the Canad

Anthos Therapeutics' Novel Factor XI Inhibitor Abelacimab Significantly Outperforms Standard of Care Enoxaparin in Prospective Phase 2 Efficacy Research Published in NEJM

CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final

Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

BOSTON--(BUSINESS WIRE)--Jul. 19, 2021 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionecto

FDA Approves Semglee (insulin glargine-yfgn) as the First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes

SILVER SPRING, Md., July 28, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in a

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 17, 2021 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s i

FDA Approves Twyneo (tretinoin and benzoyl peroxide) for the Treatment of Acne Vulgaris

NESS ZIONA, Israel, July 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica

Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management

SANTA MONICA, Calif., July 16, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and cer

GSK Announces Positive Headline Results from Five Phase 3 Studies of Daprodustat for Patients with Anemia due to Chronic Kidney Disease

Issued: London UK -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from five studies of the Phase 3 ASCEND programme, evaluating the efficacy and safety profile of dapr

Lilly and Banner Alzheimer's Institute Collaborate on Planned Phase 3 Prevention Trial of Donanemab

INDIANAPOLIS and PHOENIX, July 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the planned

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) over time NEW BRUNSWICK, N.J

Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE) July 12, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of p

Johnson & Johnson Statement on COVID-19 Vaccine Following Reports of Guillain-Barré Syndrome

NEW BRUNSWICK, N.J., July 12, 2021 -- The safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barré syndrome have be